D.A. Davidson & CO. increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 2.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 209,486 shares of the biopharmaceutical company’s stock after buying an additional 5,116 shares during the quarter. D.A. Davidson & CO.’s holdings in Bristol-Myers Squibb were worth $11,593,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $101,000. Institutional & Family Asset Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $106,000. Centerpoint Advisors LLC raised its position in shares of Bristol-Myers Squibb by 373.1% during the first quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 1,399 shares during the period. Mount Yale Investment Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $179,000. Finally, Valmark Advisers Inc. acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $202,000. Institutional investors and hedge funds own 71.39% of the company’s stock.
A number of equities research analysts have recently issued reports on BMY shares. Jefferies Financial Group reaffirmed a “hold” rating and set a $66.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, April 13th. Morgan Stanley lowered Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $54.08 to $58.00 in a research report on Tuesday, April 17th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, April 17th. Bank of America cut their target price on Bristol-Myers Squibb from $68.00 to $61.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 17th. Finally, Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Tuesday, April 17th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have given a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $63.11.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.87 by $0.14. The firm had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. Bristol-Myers Squibb’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.74 earnings per share. equities research analysts predict that Bristol-Myers Squibb Co will post 3.62 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 1st. Investors of record on Friday, July 6th were given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.69%. The ex-dividend date of this dividend was Thursday, July 5th. Bristol-Myers Squibb’s payout ratio is 53.16%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Recommended Story: Google Finance
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.